Congratulations to D2M Biotherapeutics (Beijing) Ltd. (“D2M Biotherapeutics”) on obtaining the Investigational New Drug (IND) approval from the FDA for its first pipeline product, DM919, a pan-tumor indication checkpoint inhibitor monoclonal antibody. D2M Biotherapeutics will conduct multicenter, open-label, dose escalation, and expansion clinical trials in China and the United States to evaluate the safety and clinical activity of DM919 as monotherapy and in combination with anti-PD1 monoclonal antibodies in patients with advanced solid tumors.
As the antibody CMC service provider for D2M Biotherapeutics, Zencore Biologics is honored to offer comprehensive CMC support from Sequence to IND submission, aiding D2M Biotherapeutics in obtaining IND approval for its new drug project.
Zencore Biologics sincerely wish that D2M Biotherapeutics will make smooth clinical progress and be launched as soon as possible, which will bring the hope of cure to patients. Zencore Biologics will always adhere to providing high-quality, efficient and comprehensive CDMO services for global partners.